BEST4 Surveillance Trial
Research type
Research Study
Full title
Barrett’s oESophagus Trial 4 (BEST4): A Prospective Cohort trial for the Surveillance of Barrett’s Oesophagus using a capsule sponge test and biomarker panel
IRAS ID
331813
Contact name
Massimiliano di Pietro
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
Duration of Study in the UK
1 years, 8 months, 30 days
Research summary
This trial aims to assess whether using a capsule sponge device together with a laboratory biomarker panel can be used as part of a surveillance strategy for people with non-dysplastic Barrett's oesophagus (NDBO). Using a non-endoscopic device as part of a BO surveillance strategy could be an attractive option as it can be performed in an office setting making it more convenient for patients; it is quick and easy to perform without requiring sedation; the sponge collects a sample from across the oesophagus compared to endoscopic biopsies; it may also have cost benefits for the NHS. Enrolled participants will receive the capsule sponge test, in addition to their standard of care endoscopies as part of routine BO surveillance. Upon joining the trial, participants will be allocated into a risk group using a biomarker panel (based on clinical factors and laboratory markers on capsule sponge). The frequency of follow-up for participants during this 3 year trial will depend on the risk group participants are allocated to.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
23/WM/0210
Date of REC Opinion
25 Sep 2023
REC opinion
Favourable Opinion